Objective  Rapid health technology assessment (HTA) was used to evaluate the efficacy, safety and economy of argatroban in the treatment of acute ischemic stroke, so as to provide evidence-based reference for clinical treatment decision making.

Methods  PubMed, Embase, Web of Science, Cochrane Library, CNKI, WanFang Data, VIP, SinoMed databases and HTA website were electronically searched to collect the HTA report, systematic review/Meta-analysis and pharmacoeconomic research of argatroban in the treatment of acute ischemic cerebral infarction from inception to February 6, 2024. Two reviewers independently identified studies, extracted data, assessed the quality of included studies, and descriptively analyzed and summarised the results.

Results  A total of 21 articles were included, including 15 systematic reviews/Meta-analysis and 6 pharmacoeconomic studies. The analysis results of effectiveness showed that argatroban could improve the clinical effective rate, neurological deficit score compared with placebo, routine treatment, or other drugs (such as alteplase), but a few studies were inconsistent with the current results. The analysis results of safety showed that argatroban alone or in combination with other drugs did not increase the risk of systemic hemorrhage, intracranial hemorrhage, mortality and other adverse reactions compared with the control group, and had a favorable safety profile. The analysis results of pharmacoeconomic studies that argatroban combined with routine treatment or argatroban  combined with urokinase had economic advantages.

Conclusion  Argatroban is generally effective and safe in the treatment of acute ischemic stroke, and it has economic advantages for patients to choose argatroban combined with routine treatment or urokinase treatment.

1.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J] .中华神经科杂志, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

2.张福先. 抗凝与出血管理中的争议与共识[J]. 中国实用外科杂志, 2017, 37(12): 1328-1331. [Zhang FX. Anticoagulation therapy with management of complication for hemorrhage: controversy and consensus[J]. Chinese Journal of Practical Surgery, 2017, 37(12): 1328-1331.] DOI: 10.19538/j.cjps.issn1005-2208.2017.12.04.

3.王杰. 阿加曲班对脑梗塞急性期患者血液流变指标及APTT、PT的影响[J]. 医学信息, 2022, 35(22): 130-132. [Wang J. The effect of agatroban on hemorheological parameters, APTT, and PT in patients with acute cerebral infarction[J]. Medical Information, 2022, 35(22): 130-132.] DOI: 10.3969/j.issn.1006-1959.2022.22.030.

4.北京神经科学学会血管神经病学专业委员会, 阿加曲班治疗急性缺血性卒中中国专家共识组. 阿加曲班治疗急性缺血性卒中中国专家共识2021[J]. 中国卒中杂志, 2021, 16(9): 946-953. DOI: 10.3969/j.issn.1673-5765.2021.09.012.

5.唐惠林, 门鹏, 翟所迪. 药物快速卫生技术评估方法及应用[J]. 临床药物治疗杂志, 2016, 14(2): 1-4. [Tang HL, Men P, Zhai SD. Introducing and exploring themethod of rapid review on drugs[J]. Journal of Clinical Drug Therapy, 2016, 14(2): 1-4.] DOI: 10.3969/j.issn.1672-3384.2016.02.001.

6.Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2 a crical appraisal tool for systematic reviews that include randomised or non-randomised studiesof healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. DOI: 10.1136/bmj.j4008.

7.Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations[J]. BMC Med. 2022, 20(1): 23. DOI: 10.1186/s12916-021-02204-0.

8.Hailey D. Toward transparency in health technology assessment: a checklist for HTA reports[J]. Int J Technol Assess Health Care, 2003, 19(1): 1-7. DOI: 10.1017/s0266462303000011.

9.蔡培珊, 王俊伟, 陈薇, 等. 阿加曲班联合阿替普酶治疗急性缺血性脑卒中的系统评价及GRADE证据级别评价[J]. 药物评价研究, 2022, 45(11): 2318-2328. [Cai PS, Wang JW, Chen W, et al. A systematic review and GRADE evidence level evaluation of the combination of agatroban and ateplase in the treatment of acute ischemic stroke[J]. Drug Evaluation Research, 2022, 45(11): 2318-2328.] DOl: 10.7501/j.issn.1674- 6376.2022.11.021.

10.胡寅钦, 程记伟, 孙梦, 等. 阿加曲班治疗急性缺血性卒中疗效及安全性的系统评价及Meta分析[J]. 重庆医科大学学报, 2022, 47(7): 811-820. [Hu YQ, Cheng JW, Sun M, et al. A systematic review and meta-analysis of the efficacy and safety of agatroban in the treatment of acute ischemic stroke[J]. Journal of Chongqing Medical University, 2022, 47(7): 811-820.] DOI: 10.13406/j.cnki.cyxb.003060.

11.王若兰, 韩祖成, 袁捷, 等. 阿加曲班联合阿替普酶静脉溶栓治疗急性缺血性脑卒中有效性及安全性的Meta分析[J]. 中国医药导报, 2022, 19(20): 70-74. [Wang RL, Han ZC, Yuan J, et al. Meta analysis of the efficacy and safety of intravenous thrombolysis with agatroban combined with ateplase in the treatment of acute ischemic stroke[J]. Chinese Medical Journal, 2022, 19(20): 70-74.] DOI: 10.3969/j.issn.1673-7210.2022.20.yycyzx202220017.

12.孔燕, 赵伟佳, 廖杨平, 等. 阿加曲班治疗急性缺血性卒中的系统评价[J]. 中风与神经疾病杂志, 2011, 28(9): 800-805. [Kong Y, Zhao WJ, Liao YP, et al. Systematic review of agatroban in the treatment of acute ischemic stroke[J]. Journal of Stroke and Neurology, 2011, 28(9): 800-805.] DOI: 10.19845/j.cnki.zfysjjbzz.2011.09.008.

13.曹杰, 张培, 刘晨辰. 阿加曲班联合依达拉奉治疗急性脑梗死疗效的Meta分析[J]. 微循环学杂志, 2018, 28(3): 51-57. [Cao J, Zhang P, Liu CC. Meta analysis of the efficacy of agatroban combined with edaravone in the treatment of acute cerebral infarction[J]. Journal of Microcirculation, 2018, 28(3): 51-57.] DOI: 10.3969/j.issn.1005-1740.2018.03.011.

14.刘峻峰, 林森, 周红清, 等. 阿加曲班治疗急性缺血性脑卒中有效性和安全性的系统评价[J]. 中国循证医学杂志, 2014, 14(7): 859-866. [Liu JF, Lin S, Zhou HQ, et al. Systematic review of the efficacy and safety of Agatroban in the treatment of acute ischemic stroke[J]. Chinese Journal of Evidence Based Medicine, 2014, 14(7): 859-866.] DOI: 10.7507/1672-2531.20140142.

15.Lv B, Guo FF, Lin JC, et.al. Efficacy and safety of argatroban in treatment of acute ischemic stroke: a meta-analysis[J]. World J Clin Cases, 2022, 10(2): 585-593. DOI: 10.12998/wjcc.v10.i2.585.

16.周佳君, 邵森. 阿加曲班治疗急性进展性脑梗死的Meta分析[J]. 中风与神经疾病杂志, 2014, 31(10): 932-934. [Zhou JJ, Shao S. Meta analysis of agatroban in the treatment of acute progressive cerebral infarction[J]. Journal of Stroke and Neurological Diseases, 2014, 31(10): 932-934.] DOI: CNKI:SUN:ZFSJ.0.2014-10-020.

17.石岩硕, 曹格溪, 邱学佳, 等. 阿加曲班联合阿替普酶治疗急性脑梗死的临床疗效和安全性的系统评价[J]. 中国医院用药评价与分析, 2023, 23(8): 990-994. [Shi YS, Cao GX, Qiu XJ, et al. A systematic review of the clinical efficacy and safety of agatroban combined with ateplase in the treatment of acute cerebral infarction[J]. Drug Evaluation and Analysis in Chinese Hospitals, 2023, 23(8): 990-994.] DOI: 10.14009/j.issn.1672-2124.2023.08.021.

18.张东东, 杨进超, 郑俊. 单独静脉输注阿替普酶与联合阿加曲班对急性缺血性脑卒中治疗效果的Meta分析[J]. 武汉大学学报(医学版), 2023, 44(12): 1538-1544. [Zhang DD, Yang JC, Zheng J. Meta analysis of the therapeutic effect of intravenous infusion of ateplase alone and combination with agatroban on acute ischemic stroke[J]. Journal of Wuhan University (Medical Edition), 2023, 44(12): 1538-1544.] DOI: 10.14188/j.1671-8852.2023.0357.

19.庄鸣阳, 李全福, 丁阳阳, 等. 阿加曲班联合阿替普酶治疗急性缺血性脑卒中的疗效和安全性的Meta分析[J]. 浙江临床医学, 2021, 23(11): 1654-1657. [Zhuang MY, Li QF, Ding YY, et al. Meta analysis of the efficacy and safety of agatroban combined with ateplase in the treatment of acute ischemic stroke[J]. Zhejiang Clinical Medicine, 2021, 23(11): 1654-1657.] DOI: 10.3969/j.issn.1008-7664.2021.11.zjlcyx202111042.

20.慕鸿泽. 阿加曲班治疗进展性脑梗死疗效的Meta分析[D]. 沈阳: 中国医科大学, 2014.

21.赖锦星, 卢知娟, 谢树华, 等. 阿加曲班治疗进展性脑梗死疗效的Meta分析[J]. 医药卫生, 2021(10): 7-9. [Lai JX, Lu ZJ, Xie SH, et al. Meta-analysis of the efficacy of agatroban in the treatment of progressive cerebral infarction[J]. Journal of Medicine and Health, 2021(10): 7-9.] http://qikan.cqvip.com/Qikan/Article/Detail?id=1000003267231.

22.Al-Salihi MM, Saha R, Ayyad A, et al. Efficacy and safety of argatroban in the management of acute ischemic stroke: a systematic literature review and meta-analysis[J]. Clin Neurol Neurosurg, 2024, 236: 108097. DOI: 10.1016/j.clineuro.2023.108097.

23.Chlorogiannis DD, Mavridis T, Adamou A, et al. Argatroban as an add-on to rtPA in acute ischemic stroke: a systematic review and Meta-analysis[J]. J Clin Med, 2024, 13(2): 563. DOI: 10.3390/jcm13020563.

24.吴玉波, 王伟巍, 李岩, 等. 巴曲酶和阿加曲班治疗急性缺血性脑卒中的最小成本分析[J]. 中国药师, 2011, 14(7): 1025-1026. [Wu YB, Wang WW, Li Y, et al. Minimum cost analysis of batroxobin and agatroban in the treatment of acute ischemic stroke[J]. Chinese Pharmacologist, 2011, 14(7): 1025-1026.] DOI: 10.3969/j.issn.1008-049X.2011.07.046.

25.吴玉波, 王伟巍, 李岩, 等. 3种治疗急性缺血性脑卒中药的最小成本分析[J]. 中国药房, 2011, 22(10): 865-866. [Wu YB, Wang WW, Li Y, et al. Minimum cost analysis of three traditional Chinese medicines for the treatment of acute ischemic stroke[J]. Chinese Pharmacy, 2011, 22(10): 865-866.] DOI: CNKI:SUN:ZGYA.0.2011-10-003.

26.吴惠金, 杜智敏, 张卓伯, 等. 急性缺血性脑卒中治疗的成本效果评价[J]. 牡丹江医学院学报, 2010, 31(6): 29-32. [Wu HJ, Du ZM, Zhang ZB, et al. Cost effectiveness evaluation of acute ischemic stroke treatment[J]. Journal of Mudanjiang Medical College, 2010, 31(6): 29-32.] DOI: 10.3969/j.issn.1001-7550.2010.06.010.

27.乔媛, 储秋萍. 3种依达拉奉联合用药方案治疗急性脑梗死的最小成本分析[J]. 中国药房, 2016, 27(5): 581-583. [Qiao Y, Chu QP. Minimum cost analysis of three combination therapy regimens of edaravone for the treatment of acute cerebral infarction[J]. Chinese Pharmacy, 2016, 27(5): 581-583.] DOI: 10.6039/j.issn.1001-0408.2016.05.02.

28.杨警囡. 不同方案治疗急性缺血性脑卒中的药物经济学评价[D]. 石家庄: 河北医科大学, 2022.

29.井俊凯, 胡晓婷, 时嘉彤, 等. 3种改善血液循环药物联合基础治疗用于急性脑梗死的网状Meta分析及药物经济学评价[J]. 药物评价研究, 2021, 44(3): 617-627. [Jing JK, Hu XT, Shi JT, et al. A network meta-analysis and pharmacoeconomic evaluation of three drugs for improving blood circulation combined with basic therapy for acute cerebral infarction[J]. Drug Evaluation Research, 2021, 44(3): 617-627.] DOI: 10.7501/j.issn.1674-6376.2021.03.025.

30.王哲义, 孙怿泽, 张媛凤, 等. 丹参类中药注射剂治疗急性缺血性脑卒中有效性和安全性的网状Meta分析[J]. 中国循证医学杂志, 2022, 22(2): 217-231. [Wang ZY, Sun YZ, Zhang YF, et al.Efficacy and safety of salvia miltiorrhiza injection classes in treatment of acute ischemic stroke:a network meta-analysis[J]. Chinese Journal of Evidence-Based Medicine, 2022, 22(2): 217-231.] DOI: 10.7507/1672-2531.202107133.

31.Peng Z. Efficacy and safety of agatroban in improving the prognosis of ischemic stroke patients[J]. Am J Transl Res, 2023, 15(9): 5699-5706. DOI: ISSN:1943-8141/AJTR0149105.

32.Eller T, Busse J, Dittrich M, et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests[J]. Clin Chem Lab Med, 2014, 52(6): 835-844. DOI: 10.1515/cclm-2013-0936.

33.韩春晓, 王娜. 阿加曲班药理作用和临床应用研究进展[J]. 药物评价研究, 2021, 44(10): 2088-2096. [Han CX, Wang N. Research progress on pharmacological effects and clinical applications of agatroban[J]. Drug Evaluation Research, 2021, 44(10): 2088-2096.] DOI: 10.7501/j.issn.1674-6376.2021.10.006.

34.郭道骝. 阿加曲班对于超过静脉溶栓时间窗48 h内ACI患者的效果及安全性[J]. 航空航天医学杂志, 2023, 34(5): 582-584. [Guo DL. The efficacy and safety of agatroban in ACI patients within 48 hours of intravenous thrombolysis[J]. Journal of Aerospace Medicine, 2023, 34(5): 582-584.] DOI: 10.3969/j.issn.2095-1434.2023.05.026.

35.戴亨纷, 郑彩云, 刘云春, 等. 阿加曲班药物利用评价标准的建立与应用[J]. 药物流行病学杂志, 2024, 33(2): 121-127. [Dai HF, Zheng CY, Liu YC, et al. Establishment and application of evaluation criteria for drug utilization of agatroban[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(2): 121-127.] DOI: 10.12173/j.issn.1005-0698.202312013.

36.王斌霞, 唐莲, 李兰. 1例抗磷脂综合征合并HELLP综合征患者肾脏替代治疗期间的抗凝治疗分析和药学监护[J]. 中国药师, 2022, 25(6): 1040-1044. [Wang BX, Tang L, Li L. Analysis of anticoagulant therapy and pharmaceutical monitoring during renal replacement therapy in a patient with antiphospholipid syndrome combined with HELLP syndrome[J]. Chinese Pharmacist, 2022, 25(6): 1040-1044.] DOI: 10.19962/j.cnki.issn1008-049X.2022.06.019.